672 results
P
I+C, I, C
I/C
PD-1/L1 inhibitors plus chemotherapy, PD-1/L1 inhibitors alone, chemotherapy, I+C vs I, I+C vs C, I vs C
O
risk of immune-related pneumonitis (IRP), risk of any grade IRP, risk of grade 3-5 IRP
P
CHROMATRYPSIN C
I/C
CHROMATRYPSIN C, CHROMATRYPSIN C
O
CHRONIC PANCREATITIS
P
surgical patients
I/C
peripheral levels of Insulin-like Growth Factor-1 (IGF-1), C-Reactive Protein (C-RP) and Interleukin-6 (IL-6), delirium in surgical patients
O
association between peripheral levels of IGF-1, C-RP and IL-6 and delirium
P
FinnGen, UK Biobank
I/C
vitamin C, circulating vitamin C
O
risk of small intestine and colorectal cancer
P
soil microbial extracellular hydrolytic enzymatic activities (Hy-EEAs), soil oxidative enzymatic activities (Ox-EEAs), soil carbon (C), soil nitrogen (N), soil phosphorus (P)
I/C
natural forest conversion (NFC), Changes in soil Hy- and Ox-EEAs, changes in soil organic C, available P, microbial biomass C and N
O
depletion of soil organic carbon, stimulated soil microbial secretion of Hy- and Ox-EEAs, soil total N scarcity, provoke soil microbial Hy-EEAs, soil total P dearth, quickened the soil Ox-EEAs, plenitude of soil available P, suppressed soil Hy- and Ox-EEAs
P
A/A protected donors, A/C heterozygous donors, C/C at-risk donors, adults without diabetes, adults with type 2 diabetes
I/C
genotyping rs3842753, integrating single-cell RNA sequencing data sets, β cells from females vs. males, rs3842753 C‒containing cells vs. A/A homozygous cells, β cells with the rs3842753 C allele vs. A/A homozygous genotype
O
INS expression mean and variance, endoplasmic reticulum stress marker gene expression
P
XPG rs17655G>C, XPF rs1799801T>C
I/C
CT vs. TT
O
risk of cutaneous malignant melanoma (CMM)
P
hypertensive subjects
I/C
vitamin C intake, serum vitamin C levels
O
blood pressure
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
patients with type 2 diabetes mellitus (T2DM)
I/C
low serum C-peptide level, normal C-peptide group (control group)
O
incidence of coronary heart disease, incidence of cerebral infarction, blood lipid level, lipid deposition